Affordable Access

deepdyve-link
Publisher Website

Soluble human CD83 ameliorates lupus in NZB/W F1 mice.

Authors
  • Starke, Charlotte1
  • Steinkasserer, Alexander
  • Voll, Reinhard E
  • Zinser, Elisabeth
  • 1 Department of Internal Medicine 3 and Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen-Nuremberg, Erlangen, Germany; Department of Internal Medicine 3, University of Technology, Dresden, Germany. , (Germany)
Type
Published Article
Journal
Immunobiology
Publication Date
Nov 01, 2013
Volume
218
Issue
11
Pages
1411–1415
Identifiers
DOI: 10.1016/j.imbio.2013.06.002
PMID: 23886695
Source
Medline
Keywords
License
Unknown

Abstract

In the present study we explored the immunomodulatory potential of prokaryotically expressed soluble CD83 in the treatment of murine lupus using the NZB/W F1 mouse model. Therefore female NZB/W F1 lupus mice were treated either with sCD83 or PBS for 4 weeks. sCD83 treated mice showed a significantly delayed onset of anti-dsDNA autoantibody production when compared with the control group. Importantly, during the treatment period with sCD83 none of the mice showed elevated levels of anti-dsDNA autoantibodies. In addition, NZB/W F1 mice which received sCD83 displayed lower concentrations of anti-histone IgG autoantibodies. Furthermore, there was no difference in total IgG antibodies, indicating a modulatory role for sCD83 in the production of self-reactive antibodies without decreasing total IgG. These results indicate that administration of sCD83 has profound immune-modulatory effects on the induction of autoantibodies in NZB/W F1 lupus mice and may thus be a promising approach to interfere with autoimmunity in SLE and other autoantibody-driven diseases.

Report this publication

Statistics

Seen <100 times